Sign in

CIK 0001231457 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company

GENELUX Corp

Sign in to watch
Ticker
GNLX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
operating
Phone
805-267-9889
Business address
2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE, CA, 91361
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$155,693
in 6 filings

Net −$155,693. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Reading 71 more Form 4s from the SEC; this list fills in as they're read.

Date Insider Transaction Shares Price Value Owned after
2025-11-17 Cappello Joseph Chief Technical Officer Sale −973 $5.37 $5K 156,060
2025-11-17 Smalling Ralph Head of Regulatory Sale −343 $5.37 $2K 68,823
2025-09-03 Smalling Ralph Head of Regulatory Sale −580 $3.36 $2K 69,166
2025-09-01 Zindrick Thomas President and CEO Returned to the company · Stock Option (Right to Buy) −925,000 0
2025-09-01 Zindrick Thomas President and CEO Grant or award · Stock Option (Right to Buy) +925,000 925,000
2025-09-01 Zindrick Thomas President and CEO Returned to the company · Stock Option (Right to Buy) −157,372 0
2025-09-01 Zindrick Thomas President and CEO Grant or award · Stock Option (Right to Buy) +157,372 157,372
2025-09-01 Zindrick Thomas President and CEO Returned to the company · Stock Option (Right to Buy) −23,568 0
2025-09-01 Zindrick Thomas President and CEO Grant or award · Stock Option (Right to Buy) +23,568 23,568
2025-09-01 Zindrick Thomas President and CEO Returned to the company · Stock Option (Right to Buy) −250,000 0
2025-09-01 Zindrick Thomas President and CEO Grant or award · Stock Option (Right to Buy) +250,000 250,000
2025-09-01 Yu Yong SVP, Clinical Development Returned to the company · Stock Option (Right to Buy) −207,652 0
2025-09-01 Yu Yong SVP, Clinical Development Grant or award · Stock Option (Right to Buy) +207,652 207,652
2025-09-01 Yu Yong SVP, Clinical Development Returned to the company · Stock Option (Right to Buy) −65,000 0
2025-09-01 Yu Yong SVP, Clinical Development Grant or award · Stock Option (Right to Buy) +65,000 65,000
2025-09-01 Smalling Ralph Head of Regulatory Grant or award +10,000 70,990
2025-09-01 Smalling Ralph Head of Regulatory Returned to the company · Stock Option (Right to Buy) −8,333 0
2025-09-01 Smalling Ralph Head of Regulatory Grant or award · Stock Option (Right to Buy) +8,333 8,333
2025-09-01 Cappello Joseph Chief Technical Officer Returned to the company · Stock Option (Right to Buy) −16,666 0
2025-09-01 Cappello Joseph Chief Technical Officer Grant or award · Stock Option (Right to Buy) +16,666 16,666

Page 3 of 9 · 170 trades